Continue to site >
Trending ETFs

Name

As of 04/16/2021

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$14.81

$966 M

-

1.09%

Vitals

YTD Return

-46.5%

1 yr return

48.9%

3 Yr Avg Return

18.3%

5 Yr Avg Return

16.9%

Net Assets

$966 M

Holdings in Top 10

28.0%

52 WEEK LOW AND HIGH

$14.8
$14.81
$29.83

Expenses

OPERATING FEES

Expense Ratio 1.09%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 37.00%

Redemption Fee N/A


Min Investment

Standard (Taxable)

$0

IRA

N/A


Fund Classification

Fund Type

Open End Mutual Fund


Name

As of 04/16/2021

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$14.81

$966 M

-

1.09%

VCHSX - Profile

Distributions

  • YTD Total Return -46.5%
  • 3 Yr Annualized Total Return 18.3%
  • 5 Yr Annualized Total Return 16.9%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.18%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    VALIC Company I Health Sciences Fund
  • Fund Family Name
    VALIC
  • Inception Date
    Nov 01, 2000
  • Shares Outstanding
    N/A
  • Share Class
    No Load
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Ziad Bakri

Fund Description


VCHSX - Performance

Return Ranking - Trailing

Period VCHSX Return Category Return Low Category Return High Rank in Category (%)
YTD -46.5% -46.5% 19.7% 100.00%
1 Yr 48.9% 21.1% 184.4% 27.88%
3 Yr 18.3%* 1.3% 54.0% 12.33%
5 Yr 16.9%* 5.2% 40.3% 16.43%
10 Yr 18.7%* 9.4% 20.2% 6.45%

* Annualized

Return Ranking - Calendar

Period VCHSX Return Category Return Low Category Return High Rank in Category (%)
2023 20.0% -13.6% 178.2% 29.01%
2022 18.1% 3.8% 63.8% 71.23%
2021 -10.4% -49.7% 21.5% 74.64%
2020 13.1% -59.8% 54.4% 66.91%
2019 -24.2% -36.6% 11.6% 89.92%

Total Return Ranking - Trailing

Period VCHSX Return Category Return Low Category Return High Rank in Category (%)
YTD -46.5% -46.5% 19.7% 100.00%
1 Yr 48.9% 14.7% 184.4% 26.67%
3 Yr 18.3%* 1.3% 54.0% 12.33%
5 Yr 16.9%* 5.0% 40.3% 16.43%
10 Yr 18.7%* 9.3% 20.2% 6.45%

* Annualized

Total Return Ranking - Calendar

Period VCHSX Return Category Return Low Category Return High Rank in Category (%)
2023 20.0% -13.6% 178.2% 29.01%
2022 18.1% 3.8% 63.8% 71.23%
2021 -10.4% -25.3% 22.2% 76.09%
2020 13.1% -10.8% 54.4% 76.47%
2019 -24.2% -36.6% 11.6% 96.12%

NAV & Total Return History


VCHSX - Holdings

Concentration Analysis

VCHSX Category Low Category High VCHSX % Rank
Net Assets 966 M 2.48 M 47.6 B 49.71%
Number of Holdings 267 26 450 4.57%
Net Assets in Top 10 276 M 239 K 19.6 B 52.57%
Weighting of Top 10 27.97% 7.6% 77.3% 85.71%

Top 10 Holdings

  1. UnitedHealth Group Inc 5.48%
  2. Thermo Fisher Scientific Inc 3.55%
  3. Eli Lilly and Co 3.32%
  4. Intuitive Surgical Inc 3.16%
  5. Danaher Corp 2.84%
  6. Stryker Corp 2.35%
  7. Regeneron Pharmaceuticals Inc 2.12%
  8. Amgen Inc 2.02%
  9. Merck & Co Inc 1.92%
  10. Vertex Pharmaceuticals Inc 1.88%

Asset Allocation

Weighting Return Low Return High VCHSX % Rank
Stocks
97.19% 82.66% 105.23% 73.71%
Preferred Stocks
1.66% 0.00% 5.58% 5.14%
Other
0.79% -26.63% 10.48% 17.71%
Cash
0.36% -0.23% 17.34% 65.14%
Convertible Bonds
0.00% 0.00% 0.02% 59.43%
Bonds
0.00% 0.00% 18.37% 61.71%

Stock Sector Breakdown

Weighting Return Low Return High VCHSX % Rank
Healthcare
98.85% 22.48% 100.00% 60.00%
Basic Materials
0.65% 0.00% 3.70% 20.57%
Financial Services
0.43% 0.00% 10.87% 17.71%
Technology
0.05% 0.00% 27.24% 17.14%
Energy
0.03% 0.00% 0.03% 0.57%
Utilities
0.00% 0.00% 1.24% 58.86%
Real Estate
0.00% 0.00% 6.18% 62.29%
Industrials
0.00% 0.00% 6.41% 62.86%
Communication Services
0.00% 0.00% 13.17% 61.14%
Consumer Defense
0.00% 0.00% 30.57% 59.43%
Consumer Cyclical
0.00% 0.00% 14.05% 61.71%

Stock Geographic Breakdown

Weighting Return Low Return High VCHSX % Rank
US
87.39% 58.67% 101.51% 33.71%
Non US
9.80% 0.00% 40.32% 65.14%

VCHSX - Expenses

Operational Fees

VCHSX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.09% 0.08% 25.14% 45.88%
Management Fee 0.98% 0.00% 1.25% 88.00%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee 0.06% 0.03% 0.25% 14.29%

Sales Fees

VCHSX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

VCHSX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

VCHSX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 37.00% 0.70% 252.00% 40.00%

VCHSX - Distributions

Dividend Yield Analysis

VCHSX Category Low Category High VCHSX % Rank
Dividend Yield 0.00% 0.00% 0.96% 66.29%

Dividend Distribution Analysis

VCHSX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Annually Annually

Net Income Ratio Analysis

VCHSX Category Low Category High VCHSX % Rank
Net Income Ratio -0.18% -2.53% 1.74% 60.23%

Capital Gain Distribution Analysis

VCHSX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Distributions History

View More +

VCHSX - Fund Manager Analysis

Managers

Ziad Bakri


Start Date

Tenure

Tenure Rank

Apr 01, 2016

5.0

5.0%

Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad brings a unique perspective to his new role, having been a medical doctor and an emergency medicine resident at the Royal London Hospital before beginning his investment career. Prior to joining T. Rowe Price, Ziad held biotechnology equity research and healthcare investment ban

Tenure Analysis

Category Low Category High Category Average Category Mode
0.04 23.56 7.25 20.93